Market revenue in 2022 | USD 215.5 million |
Market revenue in 2030 | USD 479.4 million |
Growth rate | 10.5% (CAGR from 2022 to 2030) |
Largest segment | 13-24 weeks |
Fastest growing segment | 0-12 weeks |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | 0-12 weeks, 13-24 weeks, 25-36 weeks |
Key market players worldwide | CooperSurgical, Natera Inc, Eurofins Scientific SE, Illumina Inc, Centogene NV Ordinary Shares, MedGenome, Myriad Genetics Inc, Roche Holding AG, Qiagen NV, Labcorp Holdings Inc, Quest Diagnostics Inc, Biora Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non invasive prenatal testing market will help companies and investors design strategic landscapes.
13-24 weeks was the largest segment with a revenue share of 51.46% in 2022. Horizon Databook has segmented the UK non invasive prenatal testing market based on 0-12 weeks, 13-24 weeks, 25-36 weeks covering the revenue growth of each sub-segment from 2018 to 2030.
NIPT is approved by the UK Genetic Testing Network only for certain specific conditions. Only high-risk pregnant women are offered NIPT, for example, women who have an indication or family history of abnormalities.
Moreover, NIPT is a safer option when compared to invasive tests. NIPT was first offered in the country in 2012. NIPT was implemented in England in July 2021, in Scotland in September 2020, and in Wales in April 2018. The growing demand for NIPT in the region can be attributed to the ease of making informed decisions post the test for management of pregnancy.
In addition, in 2016, the UK National Screening Committee suggested an approach that pregnant women with over one in 150 having a chance of aneuploidy development should be offered NIPT. Private clinics and individual clinicians are delivering NIPT supplied by a variety of different laboratories, based in the UK and overseas.
Horizon Databook provides a detailed overview of country-level data and insights on the UK non invasive prenatal testing market , including forecasts for subscribers. This country databook contains high-level insights into UK non invasive prenatal testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account